TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.
about
β-Adrenergic Receptor Signaling in Prostate CancerFunctional antagonism of TMPRSS2-ERG splice variants in prostate cancer.Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial.Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG statusERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer CellsBiomarkers for prostate cancer: present challenges and future opportunities.Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a reviewThe oncogene ERG: a key factor in prostate cancer.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Molecular biomarkers to guide precision medicine in localized prostate cancer.ERG expression in prostate cancer: biological relevance and clinical implication.Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesThe interaction of Wnt-11 and signalling cascades in prostate cancer.Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.Significance of the TMPRSS2:ERG gene fusion in prostate cancer.Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment.The context of prostate cancer genomics in personalized medicine.Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.Novel insights into chromosomal conformations in cancer.The molecular biology of prostate cancer: current understanding and clinical implications.ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.Urinary markers aiding in the detection and risk stratification of prostate cancerHigh concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
P2860
Q28084943-B2FCBEF6-46BF-4A1F-8B99-9ED35833D804Q34170544-E0EFAA77-12B5-49EB-97DA-D7C5A6AC508BQ35762852-1A8BD7A4-8FF9-42EA-9F04-607D5ECE38FAQ36381818-075CF818-A1BD-4D81-A911-8E0394439117Q37157965-713ABCE3-2372-4261-8C0C-BE52B6691719Q37474443-585B38BC-0543-4CFF-A127-144A2224C836Q37520447-62E10BB8-0B89-4AD1-A4E1-1E17855849C6Q37635618-794551FE-8060-4E82-9F9D-5095F9B00A10Q38253055-AD26D3D6-72A2-4161-A8DA-BC787DC4C8E3Q38444138-A217A815-20F3-4A05-9F49-25F514BB438BQ38644658-BEC23963-F975-4D1A-9C0E-F72EDCD84043Q38668635-BF33650F-B5A0-4BAC-98F7-132FE7C938DAQ38681610-EECC0BD7-7167-448C-B84D-49D290AFFC17Q38723072-00D2C298-D7CC-44FC-9957-1E4F0844FC31Q38774228-E2F4A048-F555-4893-ACA3-DFF2CC7E29EFQ38830221-E3BE173D-C949-4B4D-8FBC-087713BF39CDQ38924969-EDA7D1AD-2673-462B-A662-871A3D6DDBA8Q38969070-7C5E4738-245E-4743-A81A-56AA879B61E2Q39909790-BB59BE14-7FD4-4B34-A901-BE0A2C55A28DQ40067022-9B0CBBC2-374F-4496-BBF6-66FCD4103BECQ41186635-AA63BC93-F0CA-4E3A-9436-013ACD7101BBQ41839243-D92A5C02-060A-4DDF-A393-D53B61039673Q42287150-7953D0E0-374A-4E2B-9CB5-AA60201DC90AQ43269413-6EE46A91-8E50-40CC-9B54-C1F1205AB0A7Q47098649-F318C79E-EE6F-4DB2-8A82-26CB6768ED87Q49546811-96E37AC7-A277-456A-AE87-7FB189717083Q53472932-D72D9352-3FD3-4A27-B576-C39894C9EC89Q53519887-C1EBBC5E-2F41-4323-8B35-5B867A3A326DQ58562073-92B06F18-816B-49DF-B2A1-F236A81D3218Q58573182-88E55EAC-2FC9-4E25-AC74-67A403AEA4E0
P2860
TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@ast
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@en
type
label
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@ast
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@en
prefLabel
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@ast
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@en
P2093
P2860
P1433
P1476
TMPRSS2-ERG expression predict ...... iates with stromal biomarkers.
@en
P2093
Anders Bergh
Andreas Josefsson
Christina Hägglöf
Kerstin Strömvall
Peter Hammarsten
Pär Stattin
Torvald Granfors
P2860
P304
P356
10.1371/JOURNAL.PONE.0086824
P407
P50
P577
2014-02-05T00:00:00Z